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Abbreviations
BST Broad standard table
FDA Food and Drug Administration
HP Heparin sodium drug product
Mn Number-average molecular weight
Mp Peak molecular weight
Mw Weight-average molecular weight
MW Molecular weight
RSD Relative standard deviation
SD Standard deviation
SEC Size-exclusion chromatography
USP United States Pharmacopeia
Introduction
Heparin is a polysaccharide product isolated from glycosami-
noglycans of porcine mucosa (or occasionally other tissues
and species). It is a linear non-uniform polymer consisting of
alternating glucosamine and uronic acid monosaccharide res-
idues and is highly sulfated [1]. Heparin sodium drug product
(HP) used in medicine consists of chains with molecular
weight (MW) ranging from under 5,000 to over 50,000 [2].
Although HP has been used as an injectable antithrombotic
medicine for more than 70 years [3], many aspects of its
structure and purity, including its MW, have not been speci-
fied by public standards until recent years. In 2008, a number
of HP lots associated with severe adverse effects, including
fatalities, were found to have been contaminated with
oversulfated chondroitin sulfate [4]. This incident led to thor-
ough revision of compendial standards worldwide. In the
USA, the Food and Drug Administration (FDA) encouraged
the inclusion of enhanced standards for purity and identity in
the relevant monographs of the United States Pharmacopeia
(USP) including acceptance criteria for MW distribution.
Heparin originates in mast cell granules, in which it is the
polysaccharide part of the proteoglycan serglycin [5]. On
degranulation, heparin is released from mast cells and is
broken down by endogenous heparanase to fragments, most
of which are between 5 and 30 kDa in mass [6]. It is reason-
able to expect that variations in manufacturing procedures will
result in corresponding differences in the MW distribution of
the finished HP product. To ensure an acceptable degree of
consistency between HP products, and to decide what the
The findings and conclusions presented have not been formally
disseminated by the FDA and should not be construed to represent any
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limits of acceptability should be, it is desirable to ensure that
comparable results are obtained for MW determinations from
different laboratories.
Heparin is not a peptide, and even the most modern mass-
spectrometric methods are limited to short oligosaccharides [7].
Liquid chromatography with mass spectrometry has been used
to profile heparin preparations [8–10]. The technique is capable
of resolving up to about 20-mers; for larger oligomers, over-
lapping MW patterns prevent interpretation of the data. Thus, it
is not possible at present tomeasure completeMWdistributions
for HP or for low MW heparins by this method. A further
problem arises from the sequence heterogeneity of heparin. The
main repeating disaccharide structure, [-4)-α-L-
IdoA(2SO3
−)-(1→4)-α-D-Glc(NSO3
−,6SO3
−)-1-], accounts
for more than 70 % of heparin, but complexities of the biosyn-
thetic process mean that the remainder is heterogeneous in
sequence, and arranged in a way that is not predictable [11].
The severe complexity arising from variations in sequence and
in polysaccharide chain length mean that MW determinations
for heparin samples cannot be achieved with complete certainty
by current technology. It is therefore important to introduce an
element of consensus between expert laboratories both in the
characterization of a calibrant material for general use in the
analysis of HP and in the validation of the method.
Both HP and low MW heparins are non-uniform polymers,
withMWdispersion that can be described bymeans of number-
average and weight-average MWs (Mn and Mw, defined in the
Electronic supplementary material). The MW distribution of
heparin can also be presented in slice tables, indicating what
percentage of the material in question falls within a specified set
of ranges. The commonest method for the determination ofMW
profiles of non-uniform polymers is size-exclusion chromatog-
raphy (SEC), sometimes called gel permeation chromatography,
in which themacromolecular sample of interest passes through a
porous gel [12]. For a particular type of molecule, the retention
time on a suitable gel (one from which no molecules in the
sample are completely excluded or completely included) can be
related to molecular size and therefore MW by fitting an empir-
ical function such as a polynomial.
The degree of inclusion within the gel depends on the
shape of a molecule, as well as its size. For example, globular
proteins do not run through a gel column at the same rate as
linear polysaccharides of the same MW [13]. Even within the
class of linear polysaccharides, the degree of flexibility of the
chain is a factor with a strong effect on SEC retention; uni-
versal calibration for heparin using well-characterized narrow
fractions of the polysaccharide pullulan is possible only at
very high ionic strength [14]. Heparin is an unusually rigid
polysaccharide, behaving in solution as a semirigid polymer
[15, 16]. It is therefore best to establish reference materials for
heparin SEC using heparin itself [17].
For low MW heparin, derived from unfractionated heparin
by partial depolymerization, a number of methods have been
used to estimate the MW of a monodisperse or polydisperse
sample (e.g. mass spectrometry [9], or the UV/refractive index
ratio of a sample prepared by beta-elimination[18, 19]). For
unfractionated heparin, the most widely implemented method
is SEC with refractive index and light scattering detection [20,
21]. This method does not itself require calibration, and so is
suitable for the characterization of heparin-based calibrants.
Narrow standard calibrants, not completely monodisperse but
with a clearly defined peak MW (Mp), may be prepared from
native heparin by fractionation. Individual laboratories have
produced such standards on a small scale and characterized them
by viscosity measurements [22], light scattering [23], or a com-
bination of both [24]. The production of MW markers of this
type for unfractionated heparin on a large scale is a difficult task.
A broad standard is a polydisperse sample of a polymer. One
or more such standards can be used to determine the relationship
between MW and retention time in a specific chromatography
system ifMn andMw are known [12]. An alternative strategy is
to define for the broad standard a table, listing the proportion of
the sample falling above (or below) a series of MWs. This
approach to calibration of SEC columns has been used success-
fully for lowMWheparin products [25]. The calibration curve is
generated by inspection of the integrated chromatogram to find
the retention time at which the proportions above and below
particularMWsmatch the values provided in the table specific to
that calibrant. Software packages for the analysis of SEC data are
available to automate this process, which can, more laboriously,
be performed using a simple spreadsheet.
We report here on the development of a broad standard
calibrant to be established as the USP Heparin Sodium Molec-
ular Weight Calibrant reference standard, and of a simple SEC
method for determination of MW distributions of heparin sodi-
um. This project required two phases of international collabora-
tion. Phase 1 involved characterization of the calibrant material
in eight laboratories, and phase 2 involved 21 laboratories in an
assessment of the interlaboratory reproducibility of the SEC
method and in data gathering for the setting of acceptance criteria
for heparin sodium MW distribution. The resulting method is to
be incorporated into the ‘Heparin Sodium’ monograph of the
USP. For the first time, a convenient calibrant is widely available
so that direct comparison may be made between MW values for
unfractionated heparin determined by different laboratories.
Materials and methods
Details of the materials and methods used are given in the
Electronic supplementary material. The eight participating
laboratories in phase 1 of the study characterized the proposed
USP Heparin Sodium Molecular Weight Calibrant reference
standard by SEC with light scattering detection, using their
own choice of protocol. Analytical ultracentrifugation was
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then used as an independent check of the calibrant’s
performance.
The protocol distributed to the 21 participating laboratories
in phase 2 of the study is described in the Electronic supple-
mentary material. In brief, the chromatography system used
(based on a published method [2]) was as follows. A mobile
phase of 0.1 M ammonium acetate and 0.02 % sodium azide
in water was filtered through a 0.22-μm membrane. The
chromatography columns were a TSK guard column (6 mm
× 4 cm), a TSK SWXL 4000 column (7.8 mm × 30 cm) and a
TSK SWXL 3000 column (7.8 mm × 30 cm) in series, at
30 °C. The flow rate was 0.6 mL/min. Refractive index
detection was used, at the same temperature as the columns.
Data were collected, digitized and transferred to a workstation
for analysis, using SEC specialist software or a spreadsheet
capable of implementing the broad standard calibration and
reporting both mean MWs and distribution slice tables. On
each of four separate days, participants were asked to perform
duplicate analyses of the system suitability sample, and anal-
ysis of as many samples of HP as they chose.
Results and discussion
On the basis of determination of the dry weight of the ampoule
contents for the USP Heparin Sodium Molecular Weight
Calibrant reference standard, as described in the Electronic
supplementary material, participants in phase 1 of the study
were asked to assume that each ampoule of the proposed
calibrant 07/324 contained 10.0 mg.
Phase 1
The purpose of phase 1 of the study was to characterize the
proposed USP Heparin Sodium Molecular Weight Calibrant
reference standard by light-scattering-detected SEC in eight
experienced laboratories. Each laboratory received a single
HP sample for analysis, the candidate MW calibrant. This
material was a regular HP lot with particularly high polydis-
persity. Using the equipment, chromatography columns and
variable parameters of their choice, the participants obtained
results for bothMn andMw covering a range of roughly 30 %
of the maximum value, giving relative standard deviations
(RSDs) of around 10 % [listed with polydispersity (Mw/Mn)
values in Table 1]. The most obvious contributing factor to
this wide variability was the value chosen for the parameter
dn/dc, the coefficient describing the relationship between the
refractive index of a solution and the concentration of the
solute. The values used for this parameter (listed in
Table S1a) ranged between 0.141 mL/g (laboratory 6) and
0.12 mL/g (laboratory 7). When given the opportunity to
comment on the results of phase 1 of the study, laboratory 7
recalculated some of its results using other values for dn/dc
and was able to show that for the same chromatogram of the
proposed calibrant, Mw ranged from 16,403 (dn/dc=
0.141 mL/g) to 19,306 (dn/dc=0.12 mL/g). The other labora-
tories in the study all used values of dn/dc between 0.129 and
0.134 mL/g, but excluding laboratory 7, the range for Mw is
still high at 15,100–20,175. Therefore, other sources of vari-
ability between laboratories are clearly as influential as the
dn/dc value used. One potential source of variation is the type
of column used. Silica-based TSK SWXL columns were used
by several participants; others used a variety of polymer-based
columns (Table S1b). Some of the polymer columns used may
not be optimal for chromatography of unfractionated heparin,
giving chromatograms in which some material is not included
in the gel and so is eluted at the void volume. On the other
hand, silica columns sometimes shed silica particles into the
light scattering detector. Participants were asked to provide
slice table data so that a consensus broad standard table (BST)
could be derived. Two participants did not provide this data
set. The remaining six laboratories either sent full integrated
chromatograms (laboratories 3, 5, 7 and 8) or reduced data
sets (laboratories 1 and 2). A consensus BST was produced
from all the data submitted as follows; at extremes of the MW
range, where a value was not available, the data table was
populated with 0 or 100 % as appropriate. To avoid bias
Table 1 Average molecular weights (MW) and polydispersity (Mw/Mn)
for the proposed USP Heparin Sodium Molecular Weight Calibrant
Laboratorya Mn Mw Mw/Mn
1 method 1 (2) 14,935 17,955 1.202
1 method 2 (2) 15,255 20,175 1.322
2 method 1 (5) 14,008 17,626 1.258
2 method 2 (5) 13,932 17,423 1.251
3 (3) 12,200 16,397 1.344
4 (5) 13,351 17,267 1.293
5 method 1 (4) 11,735 15,330 1.307
5 method 2 (4) 12,003 15,578 1.298
5 method 3 (4) 12,675 16,910 1.335
5 method 4 (4) 14,028 17,933 1.279
6 (4) 16,065
7 method 1 (5) 15,689 19,509 1.243
7 method 2 (3) 15,532 19,318 1.244
7 method 3 (3) 15,185 19,360 1.275
7 method 4 (2) 14,873 20,023 1.346
7 method 5 (2) 16,073 20,220 1.259
7 method 6 (3) 14,370 19,880 1.383
8 (1) 11,070 15,100 1.364
Mean 13,936 17,893 1.3
SD 1,481 1,714 0.05
RSD (%) 10.6 9.6 3.7
RSD relative standard deviation, SD standard deviation
a The number of independent determinations is given in parentheses.
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towards laboratories contributing several data sets, a single
median value for the percentage of material below each MW
point was derived for each laboratory, and then the values
were combined by taking the median value of the laboratory
medians. By this means a consensus MW distribution was
determined reflecting contributions from all the participants
(shown in Fig. 1 by round markers). When given the oppor-
tunity to comment on the results of phase 1 of the study,
laboratory 4 submitted a MW distribution table for the pro-
posed calibrant that was very close to the median line (grey
line in Fig. 1).
Table S2 summarizes the data provided by each laboratory,
and the median data set that was used to derive a BST. The
data set used is shown graphically, with the median, in Fig. 1.
The resulting BST is shown in Table 2.
Sedimentation velocity analytical ultracentrifugation
Analytical ultracentrifugation was undertaken to check, by a
completely independent method, that measurements made
using the SEC method using the proposed calibrant, with the
BST from phase 1, are accurate.
Values for dn/dc for all the samples were found to be in the
range 0.130–0134 mL/g. MWs for HP samples 07/334 and
97/578 are listed in Table 3 with results from SEC calibrated
using the candidate USP Heparin Sodium Molecular Weight
Calibrant reference standard. There was excellent agreement
between Mw as determined by SEC and that obtained from
analytical ultracentrifugation. With the analytical ultracentri-
fugation measurements, it was noted that there was some
variation with both sample concentration and rotor speed. To
further investigate the MW characteristics of the samples,
multiple data sets of each sample were fit with one model
simultaneously. This results in a single MW estimate for 07/
334 of 14,400 and for 97/578 of 16,900. Notably, in every
case, there was less than 5 % difference between Mw as
calculated by SEC and that calculated by analytical
ultracentrifugation.
Phase 2
Phase 2 of the study had two aims: first, to assess the
interlaboratory reproducibility of the proposed USP mono-
graph method for MW characterization of HP; and second,
to collect MW data for numerous current lots of HP so that
suitable acceptance criteria could be set. For all the HP sam-
ples tested, participants submitted results for Mw, and in
addition the percent proportion of material within several
MW ranges as listed in Table S3.
Intralaboratory and interlaboratory reproducibility
as measured using the USP Heparin Sodium Identification
reference standard
Seventeen laboratories submitted results for the USP Heparin
Sodium Identification reference standard; these results are
shown in Table S3. The values shown are those submitted
by the participants, except for a few results from laboratory
10, readily corrected from data provided by the participant,
and laboratory 15, for which the results were recalculated
using the spreadsheets provided by the participant. Some
laboratories (19 and 20) presented more than one cycle of
4 days’work, and these have been treated as separate data sets,
giving a total of 20 data sets in all.
Participants in phase 2 of the study readily met the system
suitability requirements for Mw (Fig. 2) and Mp (as described
in the protocol for the phase 2 study; see the Electronic
supplementary material). All the laboratories met the
Fig. 1 The molecular weight
distribution of the proposed
calibrant, as determined by size-
exclusion chromatography with
light scattering detection in phase
1 of the study, involving eight
laboratories. Line styles
distinguish between laboratories;
the median line has round
markers. Results from laboratory
4 are shown in grey
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requirement for Mw, and all but one laboratory met the re-
quirement for Mp; laboratory 11 did not calculate Mp and did
not submit duplicate results for each day of the study.
Intralaboratory variability is summarized in Table S4. The
standard deviation (SD) for Mw, as measured in individual
laboratories, ranged between 22 and 272, resulting in RSD
ranging between 0.2 and 1.7 % of the mean. RSDs for the
distribution slices were very high in some laboratories for the
percentage withMw below 6,000 and the percentage withMw
below 8,000, but this is the result of low values for the mean,
not high values for the SD, so is not a good measure of
experimental precision.
Interlaboratory variability is summarized in Table S5. The
mean value for Mw was 15,944, just below the labelled value
of 16,000, with SD of 98.7, resulting in an RSD of 0.6 % of
the mean. The RSDs are higher for the distribution slices,
especially for M6000 and M8000, where the mean value is
low. All other RSDs were less than 10 %.
The interlaboratory RSD forMw of less than 1 % compares
favourably with that obtained from phase 1 (9.6 %). The
combination of simple chromatography, using defined col-
umns and conditions with a common reference material, al-
lows the direct comparison of results obtained in different
laboratories. Differences between laboratories in software, cal-
culation and integration protocols do not appear to introduce
excessive variation in the results. Results from several labora-
tories can therefore be pooled into a single set of data for the
purpose of setting the acceptance criteria for the USP ‘Heparin
sodium’ monograph. Figures 2 and 3 summarize the data
obtained, and were used in discussion of appropriate accep-
tance criteria. Figure 2a makes it clear that most of the HP lots
have Mw between 16,000 and 18,000, with no batches falling
below 15,000 or exceeding 20,000. These values are in agree-
ment with other measurements on recent lots [21]. Although
there is not a simple 1:1 correspondence between participants
and HPmanufacturers, Fig. 2a readily shows that, for example,
laboratory 2 reported no values for Mw over 17,000 and
laboratory 9 reported no values below 17,000. This indicates
that the heparin sodium products analysed by laboratory 2
have consistently lower average MWs than those analysed
by laboratory 9, implying that the characteristics of heparin
sodium products differ systematically between manufacturers.
Figure 2b summarizes the proportion of material in the lots
examined with MW over 24,000 (M24000). There is a strong
correlation between this value and Mw (r
2=0.874) and a con-
siderable range, from less than 10 % to over 20 %. There is
little correlation between M8000 (Fig. 2c) and Mw (r
2=0.139).
Figure 3 illustrates the overall distribution of material in all
the lots studied. The four MW ranges shown were chosen to
define the MW distribution for HP; values for M6000, M6000–
10000 and M10000–16000 were not used. The largest proportion
of HP in all the lots falls between 8,000 and 24,000, distrib-
uted unevenly around the midway point of 16,000; all the
heparin lots have more material in the M8000–16000 range than
in the M16000–24000 range.
Acceptance criteria for the MW distribution of heparin
sodium USP
Mw and distribution slice data were reported for 138 lots of HP
(a small number of which may be duplicates), from 13 labo-
ratories. The number of lots analysed by one laboratory
Table 2 Median broad standard table (BST) for the proposed USP
Heparin Sodium Molecular Weight Calibrant reference standard from
phase 1 of the study
MW % below MW % above MW
6,000 3.2 96.8
8,000 10.4 89.6
10,000 19.8 80.2
12,000 31.7 68.3
14,000 43.4 56.6
6,000 55.5 44.5
18,000 66.0 34.0
20,000 74.4 25.6
22,000 80.3 19.7
24,000 84.4 15.6
26,000 87.5 12.5
28,000 90.1 9.9
32,000 93.4 6.6
36,000 95.6 4.4
40,000 97.0 3.0
Table 3 MWs of two unfractionated heparins, measured using the phase
2 protocol method using the USP Heparin Sodium Molecular Weight
Calibrant with the BST from phase 1 of the study (Table 2)
Sample Mn
a Mw
a Mw (AUC)
b
07/334
Mean 12,125 14,331 14,200
SD 102.4 87.7 700
RSD (%) 0.84 0.61 4.93
97/578 (5th IS)
Mean 14,339 16,550 16,500
SD 169.0 141.7 600
RSD (%) 1.18 0.86 3.64
AUC analytical ultracentrifugation
aMean values, SD, and RSD for eight independent estimations. Mn, Mw
and polydispersity are as defined in the electronic supplementary
material.
bMw (AUC) and SD were determined by averaging the results from runs
obtained at 30,000 rpm (midpoint) with three different heparin concen-
trations: 2, 1 and 0.5 mg/mL.
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ranged from 2 to 21. Participants involved in heparin manu-
facture analysed HP lots of their own, and sometimes also
analysed material from other manufacturers. All of the partic-
ipating laboratories, except laboratory 2, provided results for
quadruplicate determinations so that the SD and RSD could be
calculated. Intralaboratory reproducibility as measured using
these HP samples was not analysed in detail, but the SD and
RSD for Mw and the distribution slices are broadly similar to
the values obtained for the system suitability sample.
Suitable acceptance criteria for the MW distribution of HP
were chosen on the basis of the data provided by the partici-
pants in phase 2 of the collaborative study for heparin lots with
current active DrugMaster Files. Certificates of analyses were
available for almost all of the samples, but those without a
certificate of analysis were removed from the data set at this
stage. Similarly, products from one participating laboratory
were found to be on the FDA’s Import Alert list, and were
excluded from further consideration for that reason. Results
from the single laboratory which did not complete the system
suitability check were, however, included as the data provided
by that participant made it clear that the intralaboratory vari-
ability for this laboratory (Table S3J) was acceptable.
Fig. 2 Values for aMw, bM24000 and cM8000 of the heparin sodium lots provided by participants, displayed in histogram format. Each box represents the
mean of duplicate determinations in the laboratory specified by its number
Fig. 3 Values for M8000, M8000–16000, M16000–24000 and M24000 for the
active pharmaceutical ingredient lots provided by the participants
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The parameters considered were Mw, M8000, M8000–16000,
M16000–24000 and M24000. Polydispersity (Mw/Mn) does not
yield explicit information about the proportions of material
in specific MW ranges, so was not considered suitable as an
acceptance criterion.
A decision was taken not to use the parameterM8000 owing
to the low interlaboratory precision of its estimations in phase
2, and its relative lack of variability between lots. In addition,
low MW heparin has low potency by anti-IIa assay [26], so
the proportion of such material is limited in lots of HP by the
necessity to meet the potency specification in the USP mono-
graph. By contrast, the parameter M24000 provided a direct
indication of the content of high MW material, potentially
relevant to problems of side effects and contamination. This
parameter was also found to be a major contributor to the
variability of the MW distribution between HP lots, with a
strong influence over the variability in Mw.
The parameters M8000–16000 and M16000–24000 account for
most of the material in HP. Setting numerical acceptance
values for these parameters was thought to be unnecessary;
the specification that the value of M8000–16000 should exceed
the value of M16000–24000 addresses, to some extent, the pos-
sible contamination of HP with compounds in a similar MW
range. This specification is also intended to discourage the
blending of failing HP lots to meet the MW criteria (e.g.
adding low MW heparin to a very high MW lot of HP).
As the spread ofMw values in the study (Fig. 3) represents a
genuine difference in products, and is not an issue of experi-
mental precision, there is no clear rationale for basing criteria
on some multiple of the SD; extreme values are not statistical
‘outliers’. No data are available to link side effects to the MW
distribution of HP, although it is known that heparin-induced
thrombocytopaenia is commoner in patients treated with HP
than with low MW heparin [27].
At present, HP products and lots differ in MW profile;
setting a standard prevents the range of MWs widening. All
brands of HP USP share the same name and description and
should be interchangeable, although currently this may not be
the case [28]. Consistency of physicochemical parameters
such as MW helps to ensure this.
Following discussion in the Unfractionated Heparin Expert
Panel and a period of public comment, the acceptance criteria
to be incorporated in the USP ‘Heparin sodium‘ monograph
[29] are as follows:
1. M24000 not more than 20 %
2. Mw between 15,000 and 19,000
3. The ratio of M8000–16000 to M16000–24000 not less than 1.0
The USP Heparin Sodium Molecular Weight Calibrant ref-
erence standard and the USP Heparin Sodium Identification
reference standard are available from the United States Pharma-
copeial Convention (http://www.usp.org/reference-standards).
The new MW method and acceptance criteria may help
avoid gross contamination with compounds differing fromHP
in MW distribution. Together with other orthogonal methods
in the newmonograph, this newmeasure will contribute to the
safety and consistency of HP.
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